By Vivonyx · Last reviewed: October 2026
If you've been reading about regenerative medicine, perhaps in research on knee arthritis or neuropathy, you've probably run into a wall of unfamiliar terms: PRP, stem cells, MSCs, "regenerative medicine." Two of the names that come up most often are Wharton's Jelly-derived MSCs and PRP. They're frequently mentioned in the same breath, but they are not the same thing. This guide walks through what each one actually is, in plain language, so you can ask sharper questions and set realistic expectations.
What are Wharton's Jelly-derived MSCs?
Mesenchymal stromal cells — usually shortened to MSCs — are a type of cell your body already contains. Researchers are interested in them largely because of the signaling molecules they release, which appear to play a role in the body's normal processes of managing inflammation and supporting tissue maintenance [2]. MSCs can be gathered from several places, and the source matters.
Wharton's Jelly is the soft, gel-like connective tissue inside the umbilical cord that cushions the cord's blood vessels. It contains a population of MSCs that researchers can isolate and study in the lab [1]. "Wharton's Jelly-derived MSCs," then, simply means mesenchymal cells collected from that specific tissue rather than from an adult donor's bone marrow or fat.
Where do they come from?
These cells come from umbilical cord tissue that is donated after a healthy, full-term birth — material that would otherwise be discarded. Donation generally involves informed consent and donor screening. Because the tissue comes from a donor, any preparation made from it is donor-derived rather than taken from the person who receives it. This is worth understanding up front, since people sometimes assume "stem cells" means embryonic cells. Wharton's jelly MSCs are not embryonic stem cells; they come from umbilical cord tissue collected after birth.
What "Day 0" means
You may come across the phrase "Day 0" cells. It's an informal label, not a formal scientific or FDA category, and it generally describes how much laboratory handling a cell preparation has had. In research settings, MSCs are usually grown and multiplied in the lab over days or weeks, a process called culturing or passaging. Laboratory studies show that cells change gradually with each round of growth, including shifts in their appearance, surface markers, gene activity and growth rate [3]. "Day 0" is used for material that hasn't gone through that expansion. The distinction is worth understanding, but it involves trade-offs. Without expansion, a preparation may contain relatively few cells: a 2026 laboratory analysis of minimally processed Wharton's jelly products found mostly connective-tissue matrix, with low viability and only rare viable MSCs [5]. How a preparation was processed tells you something about what it contains, but it doesn't predict any particular result.
Get the next article in your inbox
One short email when a new research article goes up. No spam, unsubscribe anytime.
How does this compare to PRP?
PRP, or platelet-rich plasma, is a very different starting material. It's made from your own blood. A sample is drawn and spun in a centrifuge to concentrate the platelets, which carry growth factors involved in the body's normal healing signaling. That concentrate is then injected or applied, depending on how it's being studied or used [4].
The key difference is that PRP is not a cell therapy in the way MSC preparations are. It contains your platelets and plasma, not a population of mesenchymal cells. PRP is autologous, meaning it comes from you, so questions about donor matching don't apply. Preparation methods and platelet concentrations vary widely between systems [4]. Wharton's Jelly preparations, by contrast, come from donated tissue and are studied for a different set of properties. Neither is a stronger-or-weaker version of the other; they're distinct tools built on different biology.
How does this compare to bone marrow?
Bone marrow is another common MSC source. Here the cells are drawn from the patient's own hip bone through a needle procedure, which is more invasive than a blood draw and can be uncomfortable. Bone marrow MSCs are also adult cells, meaning their biological age reflects the donor's age. Laboratory research has found that Wharton's jelly MSCs grow faster and can be expanded further in culture than adult bone marrow MSCs [1], which is one reason birth-tissue sources draw scientific interest. The trade-off is that bone marrow is autologous, while Wharton's Jelly is donor-derived.
Where the research is still evolving
Honesty matters most here. Wharton's jelly MSCs are an active area of research, with dozens of studies registered on ClinicalTrials.gov [8], but the science is still developing, and important questions remain open. Preparations can differ depending on the source tissue and how it's processed [3][5], long-term data is still being gathered, and a 2026 laboratory analysis found that some minimally processed Wharton's jelly products, which are often presented as containing living MSCs, contained few viable cells [5]. In the United States, Wharton's jelly products are not FDA-approved to treat any disease or condition, and the FDA has issued consumer advisories about unapproved regenerative medicine products [6][7]. The only FDA-approved stem cell products are blood-forming stem cells from umbilical cord blood, approved for certain blood disorders [7]. That doesn't mean the field is meaningless. It means any claim of a guaranteed outcome deserves skepticism, and it's reasonable to ask for clear, verifiable information about what a preparation contains.
FAQ
What is Wharton's jelly? Wharton's jelly is the soft, gel-like connective tissue inside the umbilical cord that cushions the cord's blood vessels. It contains a population of mesenchymal stromal cells (MSCs) that researchers can isolate and study in the lab [1]. The tissue comes from cords donated after healthy, full-term births, with informed consent and screening. Wharton's jelly MSCs are not embryonic stem cells; they come from umbilical cord tissue collected after birth.
How is Wharton's jelly different from PRP? PRP (platelet-rich plasma) is made from your own blood, spun to concentrate platelets. It isn't a cell therapy and contains no mesenchymal cells. Wharton's jelly preparations come from donated umbilical cord tissue and are studied for different properties. Neither is a stronger or weaker version of the other; they're distinct tools built on different biology.
How do Wharton's jelly MSCs compare with bone marrow MSCs? Bone marrow MSCs are usually drawn from your own hip bone, a more invasive procedure, and they're adult cells whose biological age reflects yours. Lab research has found that Wharton's jelly MSCs grow faster and can be expanded further in culture [1]. The trade-off is that bone marrow is your own tissue, while Wharton's jelly comes from a donor.
Is Wharton's jelly FDA-approved? No. In the United States, Wharton's jelly products are not FDA-approved to treat any disease or condition, and the FDA has issued consumer advisories about unapproved regenerative medicine products [6][7]. A 2026 laboratory analysis also found that some minimally processed Wharton's jelly products, which are often presented as containing living MSCs, contained few viable cells [5], so clear, verifiable product information matters.
Questions?
Vivonyx exists to help you make sense of this fast-moving field without hype. If you have questions about anything in this article, or you'd like help thinking through what to ask a provider, reach us any time at hello@vivonyx.com. We're happy to point you toward reliable, balanced information.
Related reading
Educational disclaimer: This article is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not intended to describe or suggest the treatment, cure, or prevention of any disease or condition. Cellular preparations discussed here are not FDA-approved therapies. Always consult a qualified, licensed healthcare professional before making any medical decision. Individual circumstances vary, and no specific outcome is implied or guaranteed.
References
Troyer DL, Weiss ML. Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells. 2008;26(3):591-599. PMID: 18065397. https://pubmed.ncbi.nlm.nih.gov/18065397/
Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. PMID: 21726829. https://pubmed.ncbi.nlm.nih.gov/21726829/
Wagner W, Horn P, Castoldi M, et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One. 2008;3(5):e2213. PMID: 18493317. https://pubmed.ncbi.nlm.nih.gov/18493317/
Everts P, Onishi K, Jayaram P, et al. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. Int J Mol Sci. 2020;21(20):7794. PMID: 33096812. https://pubmed.ncbi.nlm.nih.gov/33096812/
Marleau AM, Pearl JR, Juarez P, et al. Critical evaluation of compositions and clinical relevance of Wharton's jelly-derived biologics. J Transl Med. 2026;24(1):189. PMID: 41580705. https://pubmed.ncbi.nlm.nih.gov/41580705/
U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
U.S. Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes
ClinicalTrials.gov. Search results for "Wharton's jelly." U.S. National Library of Medicine. https://clinicaltrials.gov/search?term=%22Wharton%27s%20jelly%22